ELTP · Elite Pharmaceuticals Inc /NV/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $84.04M | $56.63M | $34.16M | $25.38M | $25.38M | $17.99M |
| Cost of Revenue | $43.96M | $30.27M | $17.56M | $17.47M | $13.51M | $10.02M |
| Gross Profit | $40.09M | $26.36M | $16.59M | $14.80M | $11.87M | $7.98M |
| R&D | $7.96M | $6.88M | $6.20M | $4.05M | $5.11M | $5.53M |
| SG&A | $9.00M | $7.15M | $5.12M | $4.46M | $3.32M | $3.35M |
| Total Operating Expenses | $20.49M | $15.57M | $12.92M | $9.72M | $9.76M | $10.26M |
| D&A | $1.23M | $1.32M | $1.28M | $1.21M | $1.31M | $1.32M |
| Operating Income | $19.60M | $10.79M | $3.68M | $5.07M | $2.10M | ($2.29M) |
| Interest Expense | $128.2K | $588.6K | $1.11M | $191.8K | $259.6K | $355.9K |
| Income Tax | $4.26M | ($19.65M) | $424.0K | ($1.74M) | - | - |
| Net Income | ($4.31M) | $20.11M | $3.56M | $8.90M | $5.09M | ($2.24M) |
| EPS - Basic | $0.00 | $0.02 | $0.00 | $0.01 | $0.01 | $0.00 |
| EPS - Diluted | $0.00 | $0.02 | $0.00 | $0.01 | $0.01 | $0.00 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.77M | $7.11M | $7.83M | $8.54M | $3.19M | $1.13M |
| Accounts Receivable | $29.21M | $19.45M | $3.09M | $3.06M | $3.50M | $4.11M |
| Inventory | $16.24M | $12.93M | $9.55M | $6.74M | $5.01M | $4.14M |
| Accounts Payable | $2.96M | $2.71M | $2.45M | $1.43M | $929.7K | $1.58M |
| Current Assets | $57.74M | $40.01M | $21.51M | $18.86M | $12.19M | $10.25M |
| Total Assets | $96.39M | $83.65M | $40.90M | $35.15M | $26.19M | $24.96M |
| Current Liabilities | $11.84M | $13.05M | $7.83M | $6.69M | $5.81M | $8.64M |
| Long-term Debt | - | - | - | $1.36M | $1.47M | $1.57M |
| Total Liabilities | $42.87M | $26.07M | $11.94M | $9.93M | $10.04M | $14.30M |
| Stockholders' Equity | $53.52M | $57.58M | $28.96M | $25.22M | $16.15M | $10.66M |
| Retained Earnings | ($120.70M) | ($116.39M) | ($136.50M) | ($140.06M) | ($148.96M) | ($154.05M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.46M | ($3.28M) | $3.34M | $6.51M | $3.19M | ($1.79M) |
| Investing Cash Flow | ($2.40M) | ($809.7K) | ($5.74M) | ($498.6K) | ($262.8K) | ($35.0K) |
| Financing Cash Flow | ($825.7K) | $3.39M | $1.70M | ($667.1K) | ($869.8K) | $689.5K |
| CapEx | $1.63M | $809.7K | $5.74M | - | - | - |
| Free Cash Flow | $5.83M | ($4.09M) | ($2.40M) | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 47.7% | 46.5% | 48.6% | 58.3% | 46.8% | 44.3% |
| Operating margin | 23.3% | 19.1% | 10.8% | 20.0% | 8.3% | -12.7% |
| EBITDA margin | 24.8% | 21.4% | 14.5% | 24.7% | 13.5% | -5.4% |
| Net margin | -5.1% | 35.5% | 10.4% | 35.1% | 20.0% | -12.5% |
| Free cash flow margin | 6.9% | -7.2% | -7.0% | - | - | - |
| FCF / Net income | -1.35 | -0.20 | -0.67 | - | - | - |
| R&D / Revenue | 9.5% | 12.2% | 18.2% | 16.0% | 20.1% | 30.7% |
| SG&A / Revenue | 10.7% | 12.6% | 15.0% | 17.6% | 13.1% | 18.6% |
| Effective tax rate | - | -4242.3% | 10.6% | -24.2% | - | - |
| Return on assets | -4.5% | 24.0% | 8.7% | 25.3% | 19.4% | -9.0% |
| Return on equity | -8.1% | 34.9% | 12.3% | 35.3% | 31.5% | -21.0% |
| Return on invested capital | - | - | - | 19.1% | - | - |
| Liquidity | ||||||
| Current ratio | 4.88 | 3.07 | 2.75 | 2.82 | 2.10 | 1.19 |
| Quick ratio | 3.50 | 2.08 | 1.53 | 1.81 | 1.24 | 0.71 |
| Cash ratio | 0.99 | 0.54 | 1.00 | 1.28 | 0.55 | 0.13 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.05 | 0.09 | 0.15 |
| Debt / Assets | - | - | - | 0.04 | 0.06 | 0.06 |
| Debt / EBITDA | - | - | - | 0.22 | 0.43 | - |
| Interest coverage | 152.8x | 18.3x | 3.3x | 26.4x | 8.1x | -6.4x |
| Equity multiplier | 1.80 | 1.45 | 1.41 | 1.39 | 1.62 | 2.34 |
| Liabilities / Assets | 0.44 | 0.31 | 0.29 | 0.28 | 0.38 | 0.57 |
| Efficiency | ||||||
| Asset turnover | 0.87 | 0.68 | 0.84 | 0.72 | 0.97 | 0.72 |
| Inventory turnover | 2.71 | 2.34 | 1.84 | 2.59 | 2.70 | 2.42 |
| Days sales outstanding | 127d | 125d | 33d | 44d | 50d | 83d |
| Days inventory outstanding | 135d | 156d | 199d | 141d | 135d | 151d |
| Days payable outstanding | 25d | 33d | 51d | 30d | 25d | 58d |
| Cash conversion cycle | 237d | 249d | 181d | 155d | 161d | 177d |
| Valuation | ||||||
| P / E | - | 7.5x | - | 3.0x | 6.0x | - |
| P / B | 8.8x | 2.7x | 1.0x | 1.2x | 3.5x | 6.5x |
| P / S | 5.6x | 2.7x | 0.9x | 1.2x | 2.2x | 3.9x |
| EV / EBITDA | 22.0x | 12.1x | 4.6x | 3.7x | 16.0x | - |
| Growth | ||||||
| Revenue growth (YoY) | 48.4% | 65.8% | 34.6% | 0.0% | 41.0% | 141.3% |
| Revenue CAGR (3y) | 49.1% | 30.7% | 23.8% | 50.4% | 50.4% | 23.1% |
| Revenue CAGR (5y) | 36.1% | 50.0% | 35.6% | 21.4% | 15.2% | 29.1% |
| Gross profit growth (YoY) | 52.1% | 58.8% | 12.2% | 24.7% | 48.7% | 178.2% |
| Operating income growth (YoY) | 81.7% | 193.5% | -27.5% | 140.9% | - | 75.0% |
| Net income growth (YoY) | - | 464.6% | -60.0% | 74.9% | - | 75.9% |
| EPS growth (YoY) | - | - | - | 0.0% | - | - |
| EPS CAGR (3y) | - | 26.0% | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | -70.6% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -7.1% | 98.8% | 14.8% | 56.2% | 51.6% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-03-31.
Business segments
$84.04M totalAbbreviated New Drug Applications$84.04M · 100.0%
Product / service
$84.04M totalManufacturing$81.99M · 97.6%
Licensing$2.06M · 2.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.31
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ELITE PHARMACEUTICALS INC /NV/ against the 5 most active filers in the same SIC group.